Oppenheimer Maintains Outperform on Zura Bio, Lowers Price Target to $15

Benzinga Newsdesk www.benzinga.com Negative 94.8%

Neg 94.8% Neu 0% Pos 0%

Oppenheimer analyst Justin Kim maintains Zura Bio (NASDAQ:ZURA) with a Outperform and lowers the price target from $16 to $15.